Home > Journals > Italian Journal of Vascular and Endovascular Surgery > Past Issues > Italian Journal of Vascular and Endovascular Surgery 2011 September;18(3) > Italian Journal of Vascular and Endovascular Surgery 2011 September;18(3):225-33

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  THE MANAGEMENT OF THORACIC TYPE A DISSECTIONS Freefree

Italian Journal of Vascular and Endovascular Surgery 2011 September;18(3):225-33

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Drug eluting technologies for PAOD

Tesserek J.

Department of Vascular and Endovascular Surgery, St. Bonifatius Hospital, Lingen, Germany


PDF


The natural means of peripheral peripheral arterial occlusive disease (PAOD) progress and the biologic response to intervention such as balloon dilatation are similar and the result would be the same unless they are affected by adjunctive treatment. Permanent cell driven repair mechanisms at the injury site and continuous material stress represent the Achilles heel of intervention. The need for durable mechanical support at the lesion site and inhibition of intimal hyperplasia have become the challenging goals of endovascular therapy. A variety of surface based cell inhibiting agents and stentplatforms for above (ATK) and below the knee (BTK) lesions have been used in trials with partially contradictive results. Recently published or presented data concerning drug eluting stent (DES) and drug eluting balloons (DEB) trials were reviewed and the results and conclusions are highlighted in this article.

top of page